ICG-181

N/A

Report date: 2022/05/10 11:52:39

Base Information

Drug NameICG-181

Drug Alias NameAnti-BCMA anti CD19 bispecific chimeric antigen receptor T cell therapy(Guiqidan Biomedicine)

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesiCar Bio Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesiCar Bio Therapeutics Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A